Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 5/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93766 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| SCHEMBL391028 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| SCHEMBL6674512 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| SCHEMBL1402291 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| SCHEMBL6130185 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| Glycylglycylglycine SCHEMBL98565 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| SCHEMBL6677616 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| SCHEMBL391787 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| SCHEMBL6120072 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 | |
| SCHEMBL4586328 | 1.00 | GLRA1 (0.43) | GLRA1SLC6A9OR51E2TERTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048988-A1 | CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME | CHILDREN'S NATIONAL MEDICAL CENTER | 2022-02-17 | — | — | US | claimed |
| US-5717065-A | Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-02-10 | — | — | US | claimed |
| US-12503498-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | GENZYME CORPORATION (US) | 2025-12-23 | — | — | US | disclosed |
| EP-4640239-A2 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | Genzyme Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250312475-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | SANOFI (FR) | 2025-10-09 | — | — | US | disclosed |
| EP-4608859-A1 | GLYCOENGINEERED FC VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | Ablynx N.V. (BE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4015535-B1 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | GENZYME CORP (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250206824-A1 | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | ABLYNX N.V. (BE) | 2025-06-26 | — | — | US | disclosed |
| WO-2025099632-A1 | CD25 BASED LYSOSOMAL DEGRADER AND USES THEREOF | SANOFI (FR) | 2025-05-15 | — | — | WO | disclosed |
| EP-4536676-A2 | METHODS FOR PURIFICATION OF MULTI-SPECIFIC ANTIBODIES | Sanofi (FR) | 2025-04-16 | — | — | EP | disclosed |
| US-20250066497-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | GENZYME CORPORATION | 2025-02-27 | — | — | US | disclosed |
| CN-101065397-A | A bacterial ATP synthase binding domain | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-31 | — | — | CN | disclosed |
| WO-2004035783-A9 | PROTEIN COMPLEXES OF THE TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) SIGNALLING PATHWAY | CELLZOME AG (DE) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004035783-A2 | PROTEIN COMPLEXES OF THE TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) SIGNALLING PATHWAY | CELLZOME AG (DE) | 2004-04-29 | — | — | WO | disclosed |
| CN-1263436-A | Identification of polynucleotides encoding novel helicobacter polypeptides in helicobacter genome | MERIEUX ORAVAX (FR) | 2000-08-16 | — | — | CN | disclosed |
| EP-0929681-A1 | RIFAMYCIN BIOSYNTHESIS GENE CLUSTER | Novartis AG (CH) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998007868-A1 | RIFAMYCIN BIOSYNTHESIS GENE CLUSTER | NOVARTIS AG (CH) | 1998-02-26 | — | — | WO | disclosed |
| EP-0638122-A1 | CDNA SEQUENCE OF DENGUE VIRUS SEROTYPE 1 (SINGAPORE STRAIN) | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993022440-A1 | CDNA SEQUENCE OF DENGUE VIRUS SEROTYPE 1 (SINGAPORE STRAIN) | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 1993-11-11 | — | — | WO | disclosed |
| WO-1992013103-A1 | INHERITED AND SOMATIC MUTATIONS OF APC GENE IN COLORECTAL CANCER OF HUMANS | THE JOHNS HOPKINS UNIVERSITY (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066497-A1 | SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING | SIGLEC9, SIGLEC7, STT3B | GLRA1 1155/4885SLC6A9 1173/4885OR51E2 1178/4885 |
| US-12503498-B2 | Fc containing polypeptides with altered glycosylation and reduced effector function | FCGR3B, FCGRT, FCGR2A | GLRA1 2436/4885SLC6A9 3478/4885OR51E2 2465/4885 |
| US-20250312475-A1 | BIVALENT, BISPECIFIC BINDING PROTEINS FOR PREVENTION OR TREATMENT OF HIV INFECTION | CD4, HAVCR2, TIMCC | GLRA1 2131/4885SLC6A9 4536/4885OR51E2 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.